RxSight, Inc. (NASDAQ:RXST) Insider Ilya Goldshleger Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $48.01, for a total transaction of $148,831.00. Following the transaction, the insider now owns 42,246 shares in the company, valued at approximately $2,028,230.46. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ilya Goldshleger also recently made the following trade(s):

• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total transaction of $149,606.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $49.02, for a total value of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $49.29, for a total value of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total value of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total transaction of $353,250.00.

RxSight Stock Up 2.1 %

NASDAQ RXST opened at $49.25 on Wednesday. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The business has a 50-day moving average price of $51.45 and a 200-day moving average price of $53.89. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -39.09 and a beta of 1.20.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The business had revenue of $34.89 million during the quarter, compared to the consensus estimate of $32.33 million. During the same period in the prior year, the company posted ($0.40) EPS. The firm’s revenue for the quarter was up 67.6% compared to the same quarter last year. Research analysts expect that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Analysts Set New Price Targets

RXST has been the topic of several recent research reports. Oppenheimer decreased their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Wells Fargo & Company cut their price target on RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Stifel Nicolaus decreased their price objective on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, BTIG Research boosted their price objective on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $60.14.

Hedge Funds Weigh In On RxSight

Several institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP bought a new position in shares of RxSight during the 1st quarter valued at about $1,929,000. Principal Financial Group Inc. boosted its stake in RxSight by 298.5% during the first quarter. Principal Financial Group Inc. now owns 34,928 shares of the company’s stock valued at $1,802,000 after buying an additional 26,164 shares during the last quarter. Baillie Gifford & Co. bought a new position in RxSight during the first quarter valued at approximately $3,429,000. M&G Plc bought a new stake in RxSight in the 1st quarter worth approximately $7,354,000. Finally, Parkman Healthcare Partners LLC raised its holdings in shares of RxSight by 34.5% during the 4th quarter. Parkman Healthcare Partners LLC now owns 513,032 shares of the company’s stock worth $20,685,000 after acquiring an additional 131,701 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.